HOME >> BIOLOGY >> NEWS
Clinical Trials Show That Bone Marrow Transplant And Vitamin A Derivative Both Improve Survival From Neuroblastoma

LOS ANGELES -- Two innovative treatments -- bone marrow transplant and follow-up therapy with high doses of retinoic acid, a derivative of Vitamin A -- significantly improve the disease-free survival of children with high-risk neuroblastoma, the third most common childhood cancer.

Researchers at the University of California San Francisco and Childrens Hospital Los Angeles, working with the nationwide Children's Cancer Group, reported those findings from a randomized study of 539 children in two separate sessions at the annual meeting of the American Society for Clinical Oncology (ASCO) at the Los Angeles Convention Center on Monday, May 18.

"The improved survival rates came without a significant increase in toxic side effects or extra days in the hospital. We recommend that these therapies should be incorporated into future treatment regimens," said Katherine K. Matthay, M.D., director of the Children's Cancer Group neuroblastoma study. She is a professor of pediatrics at the University of California San Francisco and director of pediatric clinical oncology for Lucile Packard Children's Health Services at UCSF.

Matthay reported at ASCO on the bone marrow transplant results. C. Patrick Reynolds, MD, PhD, of Childrens Hospital Los Angeles (CHLA), reported on the retinoic acid stage of the trial. Reynolds is associate professor of pediatrics and pathology at the University of Southern California School of Medicine. He also described the research in an ASCO-sponsored press briefing on Sunday (May 17).

The study, a Phase III randomized trial designed to test the efficacy of the treatment, began in 1991 and was conducted at more than 100 medical centers. It showed a significant increase in event-free survival for children who received autologous purged bone marrow transplants. Results were even more dramatic for those whose initial therapy was followed up with high doses of 13-cis retinoic acid, a Vitamin A derivative commonly prescribed for acne under
'"/>

Contact: Janet Basu
janbasu@itsa.ucsf.edu
(415) 476-2557
University of California - San Francisco
18-May-1998


Page: 1 2 3

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study reports findings of combination therapy with DOXIL
9. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
10. Clinical trial shows timing of chemotherapy improves survival in breast cancer
11. Clinical services must catch up

Post Your Comments:
(Date:6/18/2013)... , June 19, 2013  Paris Air Show ... Geotest-Marvin Test Systems) , a leading provider of ... industries, is demonstrating its solutions this week at ... 3-C82. With growing challenges including increasingly complex armament ... efficient, feature-rich, specialized aerospace test solutions that address ...
(Date:6/18/2013)... University of Calgary,s Faculty of Medicine have discovered a ... harmful bacteria. Platelets, a component of blood typically associated ... bacteria, and upon detection, seal it off from the ... in Nature Immunology this week, provide the ... "The science community has known that platelets do participate ...
(Date:6/18/2013)... from the United Kingdom, the Energy Department,s National ... Kentucky have recently published a paper describing a ... Limnoria quadripunctata , commonly known as the ... they exhibit a relatively unique ability to produce ... to break down the biomass they eat. New ...
Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Immunity mechanism discovered 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2
(Date:6/19/2013)... BioConvergence team members Curtis Strother ... 2013’s BioLogistics Summit in San Francisco earlier this ... Chain IQ and IQPC, addressed the increasingly complex ... part, attributed to current trends of globalization, outsourcing, ... trends is an increase in movement, which is ...
(Date:6/19/2013)... Toronto, Canada (PRWEB) June 19, 2013 ... clinical trial business can potentially be worth up ... With this opportunity, the Indian government is taking ... clinical trials the process. , This presentation will ... clinical trial regulations ,     Immediate and long ...
(Date:6/19/2013)... Austin, TX (PRWEB) June 19, 2013 ... new application report that details the measurement of sulfur ... NEX QC+ high resolution benchtop EDXRF analyzer . ... with standard test method ISO 13032. This International ... method for the determination of sulfur content in automotive ...
(Date:6/19/2013)... 2013 A new look at “big ... other trends will highlight technical sessions at SPIE ... In its 33rd year, the three-day event is the ... key suppliers, approximately 100 technical presentations and numerous networking ... society for optics and photonics , the meeting will ...
Breaking Biology Technology:BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3
Cached News: